Salazar, JuanMorillo, ValerySuárez, María K.Castro, AnaRamírez, PaolaRojas, MilagrosAñez, RobertoD'Marco Gascón, Luis GerardoChacín González, MaricarmenBermúdez, ValmoreProducción Científica UCH 2023UCH. Departamento de Medicina y Cirugía2024-09-132024-09-132023Salazar, J., Morillo, V., Suárez, M.K., Castro, A., Ramírez, P., Rojas, M., Añez, R., D'Marco, L., Chacín-González, M. & Bermúdez, V. (2023). Role of Gut Microbiome in Atherosclerosis: molecular and therapeutic aspects. Current Cardiology Reviews, vol. 19, i. 4, art. e020223213408. DOI. https://doi.org/10.2174/1573403X196662302021645241573-403X1875-6557 (Electrónico)http://hdl.handle.net/10637/16166Este recurso no está disponible en acceso abierto por política de la editorial.Atherosclerosis is one of the most relevant and prevalent cardiovascular diseases of our time. It is one of the pathological entities that increases the morbidity and mortality index in the adult population. Pathophysiological connections have been observed between atherosclerosis and the gut microbiome (GM), represented by a group of microorganisms that are present in the gut. These microorganisms are vital for metabolic homeostasis in humans. Recently, direct and indirect mechanisms through which GM can affect the development of atherosclerosis have been studied. This has led to research into the possible modulation of GM and metabolites as a new target in the prevention and treatment of atherosclerosis. The goal of this review is to analyze the physiopathological mechanisms linking GM and atherosclerosis that have been described so far. We also aim to summarize the recent studies that propose GM as a potential target in atherosclerosis management.enrestricted accessAteroesclerosisAtherosclerosisEnfermedad cardiovascularCardiovascular diseasesTratamiento médicoMedical treatmentArtículohttps://doi.org/10.2174/1573403X19666230202164524https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es